<?xml version='1.0' encoding='utf-8'?>
<document id="16109627"><sentence text="Protein binding characteristics of 2'-benzoyloxycinnamaldehyde."><entity charOffset="35-62" id="DDI-PubMed.16109627.s1.e0" text="2'-benzoyloxycinnamaldehyde" /></sentence><sentence text="The protein binding characteristic of 2'-Benzoyloxycinnamaldehyde (BCA) was investigated, which has demonstrated a potent antitumor effect against several human solid tumor cell lines and in human tumor xenograft nude mice"><entity charOffset="38-65" id="DDI-PubMed.16109627.s2.e0" text="2'-Benzoyloxycinnamaldehyde" /><entity charOffset="67-70" id="DDI-PubMed.16109627.s2.e1" text="BCA" /><pair ddi="false" e1="DDI-PubMed.16109627.s2.e0" e2="DDI-PubMed.16109627.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16109627.s2.e0" e2="DDI-PubMed.16109627.s2.e1" /></sentence><sentence text=" Protein binding of BCA in human serum was 86 +/- 0"><entity charOffset="20-22" id="DDI-PubMed.16109627.s3.e0" text="BCA" /></sentence><sentence text="91% and the predominant binding protein of BCA was fatty-acid-free human serum albumin (HSA) (81 +/- 0"><entity charOffset="51-61" id="DDI-PubMed.16109627.s4.e0" text="fatty-acid" /><entity charOffset="43-52" id="DDI-PubMed.16109627.s4.e1" text="BCA" /><pair ddi="false" e1="DDI-PubMed.16109627.s4.e1" e2="DDI-PubMed.16109627.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16109627.s4.e1" e2="DDI-PubMed.16109627.s4.e0" /></sentence><sentence text="91%)" /><sentence text=" The binding of BCA to HSA was outlined by one class, and Ka and n of BCA were 1"><entity charOffset="16-18" id="DDI-PubMed.16109627.s6.e0" text="BCA" /><entity charOffset="70-72" id="DDI-PubMed.16109627.s6.e1" text="BCA" /><pair ddi="false" e1="DDI-PubMed.16109627.s6.e0" e2="DDI-PubMed.16109627.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16109627.s6.e0" e2="DDI-PubMed.16109627.s6.e1" /></sentence><sentence text="65 x 10(5) M(- 1) and 0" /><sentence text="374, respectively" /><sentence text=" Displacement studies with fluorescence probes suggested that BCA mainly binds to site I on HSA, and BCA-induced enhancement in site II binding"><entity charOffset="62-64" id="DDI-PubMed.16109627.s9.e0" text="BCA" /><entity charOffset="101-103" id="DDI-PubMed.16109627.s9.e1" text="BCA" /><pair ddi="false" e1="DDI-PubMed.16109627.s9.e0" e2="DDI-PubMed.16109627.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16109627.s9.e0" e2="DDI-PubMed.16109627.s9.e1" /></sentence><sentence text=" The limited drug-drug interaction experiments suggested that BCA influences both site I and site II drug-HSA bindings via different mechanisms; a competitive displacement and a probable allosteric conformational change in HSA, respectively"><entity charOffset="62-64" id="DDI-PubMed.16109627.s10.e0" text="BCA" /></sentence><sentence text="" /></document>